Deep TMS (Trans-Cranial Magnetic Stimulation) is a newly-approved treatment by the FDA for difficult-to-treat (refractory) depression that directly regulates and improves the functioning of the brain. A magnetic coil over the Frontal lobe of the brain creates an electrical current which depolarizes nerve cells to create beneficial emotional effects much faster than medications are able to. Additionally, it is an effective and very safe option for depression that has not responded to any medication or therapy, with efficacy in non-psychotic depression that is comparable to ECT (Electroconvulsive therapy). The essential difference is that TMS does not involve general anesthesia, time off from work and some of the temporary memory problems that are seen with ECT.
This treatment modality is now available at The Emologic Clinic. The patient’s appropriateness for this treatment will be decided based on the results of the initial and subsequent sessions, in consultation with the clinic’s providers. If you are interested in more information about TMS or Deep TMS, please call 417-243-7777 Ext 209.
We will use Brainsway’s TMS machine. Brainsway’s TMS therapy is effective, safe and generally well-tolerated for patients with treatment-resistant depression. It is FDA cleared for patients who have tried several types of antidepressants without significant benefit. Brainsway’s Deep TMS therapy is non-invasive, does not generate systemic side effects, and does not require hospitalization or anesthesia.
Efficacy of Brainsway Deep TMS for Depression
Levkovitz Y, Harel EV, Roth Y et al. Deep transcranial magnetic stimulation of the prefrontal cortex – Effectiveness in major depression. Brain Stimul 2009;2:188-200.
Isserles M, Rosenberg O, Dannon P et al. Cognitive emotional reactivation during deep transcranial magnetic stimulation over the prefrontal cortex of depressive patients affects antidepressant outcomes. J Affect Disord 2011;128:235-42.
Harel EV, Rabany L, Deutsch L, Bloch Y, Zangen A, Levkovitz Y. H-coil repetitive transcranial magnetic stimulation for treatment resistant major depressive disorder: An 18-week continuation safety and feasibility study. World J Biol Psychiatry. 2014 May;15(4):298-306.
Rosenberg O, Zangen A, Stryjer R et al. Response to deep TMS in depressive patients with previous electroconvulsive treatment. Brain Stimul 2010;3:211-217.
Rosenberg O, Shoenfeld N, Zangen A et al. Deep TMS in a resistant major depressive disorder: A brief report. DepressAnxiety 2010;27:465-469.
Rosenberg O, Isserles M, Levkovitz Y et al. Effectiveness of a second deep TMS in depression: A brief report. Prog Neuropsychopharmacol Biol Psychiat 2011;35:1041-1044.
Levkovitz Y, Isserles M, Padberg F, Lisanby SH, Bystritsky A, Xia G, Tendler A, et al. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. World Psychiatry 2015;14(1):64-73.
Harvey PO, Van den Eynde F, Zangen A, Berlim MT. Neural correlates of clinical improvement after deep transcranial magnetic stimulation (DTMS) for treatment-resistant depression: a case report using functional magnetic resonance imaging. Neurocase. 2015;21(1):16-22.
Berlim MT, Van den Eynde F, Tovar-Perdomo S, Chachamovich E, Zangen A, Turecki G. Augmenting antidepressants with deep transcranial magnetic stimulation (DTMS) in treatment-resistant major depression. World J Biol Psychiatry. 2014;15(7):570-578.
Multicenter trial leading to Brainsway’s FDA Clearance for Treating Depression
Levkovitz Y. et al. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective, multi-center, randomized, controlled trial. World Psychiatry, 2015; Vol.14, 64-73.
Tolerance and Side Effects of Brainsway Deep TMS
Levkovitz Y. et al. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective, multi-center, randomized, controlled trial. World Psychiatry, 2015; Vol.14, 64-73.